Management of a case of neuroleptic malignant syndrome with bromocriptine

Neuroleptic malignant syndrome, a rare but potentially fatal side effect of antipsychotic medications, has often proven refractory to conventional antiparkinsonian medications. The authors report a dramatic response of this syndrome to the dopamine agonist bromocriptine mesylate in a patient receiving fluphenazine decanoate.